Profile of PROTHENA CORP PLC(NASDAQ:PRTA) stock

PROTHENA CORP PLC54.96

NASDAQ:PRTA (1/30/2023, 7:16:30 PM)-2.16 (-3.78%)

After market: 54.96 0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-03 2022-11-03/amc	Earnings (Next)	02-13 2023-02-13
Ins Owners	0.04%	Inst Owners	86.27%
Market Cap	2.84B	Shares	51.63M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	86.67
IPO	12-21 2012-12-21

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The firm is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The firm's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.

Company Info

PROTHENA CORP PLC

77 Sir John Rogersons Quay, Block C, Grand Canal Docklands

DUBLIN D02 VK60

P: 35312362500.0

CEO: Gene G. Kinney

Employees: 82

Website: http://www.prothena.com/

PRTA News

2 months ago - Seeking AlphaProthena prices 3.25M shares public offering (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) priced an underwritten public offering of 3.25M shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering...